BR112013010126A8 - polimorfo, composto, composição farmacêutica, uso do polimorfo ou sal, e, método de tratar um distúrbio mediado pela atividade inapropriada de pi3-cinase - Google Patents
polimorfo, composto, composição farmacêutica, uso do polimorfo ou sal, e, método de tratar um distúrbio mediado pela atividade inapropriada de pi3-cinaseInfo
- Publication number
- BR112013010126A8 BR112013010126A8 BR112013010126A BR112013010126A BR112013010126A8 BR 112013010126 A8 BR112013010126 A8 BR 112013010126A8 BR 112013010126 A BR112013010126 A BR 112013010126A BR 112013010126 A BR112013010126 A BR 112013010126A BR 112013010126 A8 BR112013010126 A8 BR 112013010126A8
- Authority
- BR
- Brazil
- Prior art keywords
- polymorph
- inappropriate
- treating
- salt
- compound
- Prior art date
Links
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 title 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1018124.6A GB201018124D0 (en) | 2010-10-27 | 2010-10-27 | Polymorphs and salts |
GB1018124.6 | 2010-10-27 | ||
PCT/EP2011/068604 WO2012055846A1 (en) | 2010-10-27 | 2011-10-25 | Polymorphs and salts of 6-(1h-indol-4-yl)-4-(5- { [4-(1-methylethyl)-1-pi perazinyl] methyl} -1,3-oxazol-2-yl)-1h-indazole as pi3k inhibitors for use in the treatment of e.g. respiratory disorders |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112013010126A2 BR112013010126A2 (pt) | 2016-09-06 |
BR112013010126A8 true BR112013010126A8 (pt) | 2018-01-23 |
BR112013010126B1 BR112013010126B1 (pt) | 2021-05-25 |
Family
ID=43365584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013010126-1A BR112013010126B1 (pt) | 2010-10-27 | 2011-10-25 | polimorfo, composto, composição farmacêutica, e, uso do polimorfo ou sal |
Country Status (26)
Country | Link |
---|---|
US (1) | US8993576B2 (pt) |
EP (2) | EP2632921B1 (pt) |
JP (1) | JP5894603B2 (pt) |
KR (1) | KR101774026B1 (pt) |
CN (1) | CN103270037B (pt) |
AU (1) | AU2011322649B2 (pt) |
BR (1) | BR112013010126B1 (pt) |
CA (1) | CA2814436C (pt) |
CY (1) | CY1121248T1 (pt) |
DK (1) | DK2632921T3 (pt) |
EA (1) | EA022872B1 (pt) |
ES (1) | ES2703716T3 (pt) |
GB (1) | GB201018124D0 (pt) |
HR (1) | HRP20182059T1 (pt) |
HU (1) | HUE042754T2 (pt) |
IL (1) | IL225704A (pt) |
LT (1) | LT2632921T (pt) |
MX (1) | MX347619B (pt) |
PL (1) | PL2632921T3 (pt) |
PT (1) | PT2632921T (pt) |
RS (1) | RS58072B1 (pt) |
SG (1) | SG189179A1 (pt) |
SI (1) | SI2632921T1 (pt) |
TR (1) | TR201819939T4 (pt) |
WO (1) | WO2012055846A1 (pt) |
ZA (1) | ZA201302480B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2526966T3 (es) | 2008-06-05 | 2015-01-19 | Glaxo Group Limited | Compuestos novedosos |
ATE552255T1 (de) | 2008-06-05 | 2012-04-15 | Glaxo Group Ltd | 4-aminoindazole |
WO2009147188A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Benzpyrazol derivatives as inhibitors of pi3 kinases |
JP5656880B2 (ja) | 2009-03-09 | 2015-01-21 | グラクソ グループ リミテッドGlaxo Group Limited | Pi3キナーゼの阻害剤としての4−オキサジアゾール−2−イル−インダゾール |
AU2010243613B2 (en) | 2009-04-30 | 2015-05-07 | Glaxo Group Limited | Oxazole substituted indazoles as PI3-kinase inhibitors |
US9326987B2 (en) * | 2010-09-08 | 2016-05-03 | Glaxo Group Limited | Indazole derivatives for use in the treatment of influenza virus infection |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
JP5965484B2 (ja) * | 2012-07-27 | 2016-08-03 | 佐藤製薬株式会社 | ジフルオロメチレン化合物 |
US9737521B2 (en) | 2012-11-08 | 2017-08-22 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor |
AU2014336251A1 (en) * | 2013-10-17 | 2016-04-14 | Glaxosmithkline Intellectual Property Development Limited | PI3K inhibitor for treatment of respiratory disease |
RU2016112268A (ru) | 2013-10-17 | 2017-11-22 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Ингибитор PI3K для лечения респираторного заболевания |
GB201509492D0 (en) * | 2015-06-02 | 2015-07-15 | Glaxosmithkline Ip Dev Ltd | Novel processes |
Family Cites Families (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
AU677776B2 (en) | 1992-04-02 | 1997-05-08 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
DE69529101T2 (de) | 1994-06-15 | 2003-11-13 | Wellcome Found | Zwischenprodukte verwendbar in der Herstellung von Enzym-Inhibitoren |
TR199701167T1 (xx) | 1995-04-14 | 1998-03-21 | Glaxo Wellcome Inc. | Albuterol i�in �l��lm�� doz inhaleri. |
MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
TW533865U (en) | 1997-06-10 | 2003-05-21 | Glaxo Group Ltd | Dispenser for dispensing medicament and actuation indicating device |
AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
DE69918422T2 (de) | 1998-03-14 | 2005-08-11 | Altana Pharma Ag | Phthalazinone als PDE3/4 Inhibitoren |
GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
US6390291B1 (en) | 1998-12-18 | 2002-05-21 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
US6352152B1 (en) | 1998-12-18 | 2002-03-05 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
US6315112B1 (en) | 1998-12-18 | 2001-11-13 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
US6119853A (en) | 1998-12-18 | 2000-09-19 | Glaxo Wellcome Inc. | Method and package for storing a pressurized container containing a drug |
CN1353717A (zh) | 1999-05-04 | 2002-06-12 | 莱加制药公司 | 四环黄体酮受体调节剂化合物及其方法 |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
IL154175A0 (en) | 2000-08-05 | 2003-07-31 | Glaxo Group Ltd | 17. beta.-carbothioate 17. alpha-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents |
AR035205A1 (es) | 2000-09-29 | 2004-05-05 | Glaxo Group Ltd | Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas |
GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
WO2002067683A1 (en) | 2001-02-26 | 2002-09-06 | Merck & Co., Inc. | Hiv protease inhibitors supported on cation exchange resins for oral administration |
DE60220887T2 (de) | 2001-03-08 | 2008-02-28 | Glaxo Group Ltd., Greenford | Agonisten von beta-adrenorezeptoren |
WO2002076933A1 (en) | 2001-03-22 | 2002-10-03 | Glaxo Group Limited | Formailide derivatives as beta2-adrenoreceptor agonists |
AU2002246397B2 (en) | 2001-04-16 | 2005-03-24 | Tanabe Seiyaku Co., Ltd. | Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence |
AU2002253342B2 (en) | 2001-04-30 | 2007-01-04 | Glaxo Group Limited | Novel anti-inflammatory androstane derivatives |
ATE399174T1 (de) | 2001-06-12 | 2008-07-15 | Glaxo Group Ltd | Neue anti inflammatorische 17.alpha.- heterozyklische ester von 17.beta.-carbothioat androstan derivativen |
CA2452114C (en) | 2001-06-26 | 2010-11-16 | Takeda Chemical Industries, Ltd. | Tgf-.beta. superfamily production/secretion promoter |
CA2458534C (en) | 2001-09-14 | 2011-11-01 | Glaxo Group Limited | Phenethanolamine derivatives for treatment of respiratory diseases |
WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
WO2003051847A1 (en) | 2001-12-19 | 2003-06-26 | Smithkline Beecham P.L.C. | (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors |
AU2003202216A1 (en) | 2002-01-14 | 2003-07-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
EP1467730A4 (en) | 2002-01-22 | 2010-03-10 | Univ California | Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof |
TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
DK1490062T3 (da) | 2002-03-26 | 2008-04-28 | Boehringer Ingelheim Pharma | Glukokortikoidmimetika, fremgangsmåder til fremstilling deraf, farmaceutiske sammensætninger og anvendelser deraf |
EP1490317A1 (en) | 2002-03-26 | 2004-12-29 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
WO2003086294A2 (en) | 2002-04-11 | 2003-10-23 | Merck & Co., Inc. | 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
ATE381535T1 (de) | 2002-04-25 | 2008-01-15 | Glaxo Group Ltd | Phenethanolaminderivate |
US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
EP1519723A1 (en) | 2002-06-27 | 2005-04-06 | Novo Nordisk A/S | Novel glucagon antagonists/inverse agonists |
EP1521733B1 (en) | 2002-07-08 | 2014-08-20 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
PL375442A1 (en) | 2002-07-18 | 2005-11-28 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
AU2003259068B2 (en) | 2002-08-09 | 2009-07-02 | Astrazeneca Ab | "1,2,4"oxadiazoles as modulators of metabotropic glutamate receptor-5 |
CA2495179A1 (en) | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
CN1691944A (zh) | 2002-08-09 | 2005-11-02 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体-5调节剂的噁二唑 |
US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
US6858627B2 (en) | 2002-08-21 | 2005-02-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
WO2004024728A2 (en) | 2002-09-16 | 2004-03-25 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors |
JP4520309B2 (ja) | 2002-09-20 | 2010-08-04 | メルク・シャープ・エンド・ドーム・コーポレイション | 選択的糖質コルチコイド受容体調節剤としてのオクタヒドロ−2−H−ナフト[1,2−f]インドール−4−カルボキサミド誘導体 |
GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
WO2004037807A2 (en) | 2002-10-22 | 2004-05-06 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
PT1556342E (pt) | 2002-10-28 | 2008-04-28 | Glaxo Group Ltd | Derivado de fenetanolamina para o tratamento de doenças respiratórias |
GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
KR20060070486A (ko) | 2003-06-13 | 2006-06-23 | 젠타리스 게엠베하 | 포스파티딜이노시톨 3-키나제의 억제 활성을 갖는 화합물및 이의 사용 방법 |
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
GB0320197D0 (en) | 2003-08-28 | 2003-10-01 | Novartis Ag | Organic compounds |
TW200811172A (en) | 2003-10-14 | 2008-03-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
ES2426288T3 (es) | 2003-10-15 | 2013-10-22 | Ube Industries, Ltd. | Novedoso derivado de imidazol |
PL1699512T3 (pl) | 2003-11-03 | 2012-11-30 | Glaxo Group Ltd | Urządzenie do dozowania płynów |
AR046225A1 (es) | 2003-11-04 | 2005-11-30 | Glaxo Group Ltd | Compuesto de 8-azoniabiciclo(3.2.1)octano, composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos que lo comprende y uso del compuesto para preparar dicha composicion |
CA2557004A1 (en) | 2003-12-19 | 2005-06-30 | Glaxo Group Limited | Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors |
WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
CN100432075C (zh) | 2004-02-04 | 2008-11-12 | 神经研究公司 | 作为烟碱样乙酰胆碱受体配体的二氮杂双环芳基衍生物 |
GB0405933D0 (en) | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
WO2005090352A1 (en) | 2004-03-16 | 2005-09-29 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor |
GB0405937D0 (en) | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
UY28871A1 (es) | 2004-04-27 | 2005-11-30 | Glaxo Group Ltd | Antagonistas del receptor de acetilcolina muscarinico |
EP1758580A4 (en) | 2004-06-24 | 2008-01-16 | Incyte Corp | N-SUBSTITUTED PIPERIDINE AND ITS USE AS A MEDICAMENT |
WO2006000398A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators |
WO2006000401A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | Substituted oxazines as glucocorticoid receptor modulators |
GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
CA2584318A1 (en) | 2004-10-19 | 2006-05-04 | F. Hoffmann-La Roche Ag | Quinoline derivatives |
JP2008520700A (ja) | 2004-11-18 | 2008-06-19 | インサイト・コーポレイション | 11−βヒドロキシルステロイドデヒドロゲナーゼタイプIの阻害剤およびその使用方法 |
US20060135540A1 (en) | 2004-11-30 | 2006-06-22 | Jack Lin | PPAR active compounds |
ATE517908T1 (de) | 2005-01-10 | 2011-08-15 | Glaxo Group Ltd | Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände |
US20090124588A1 (en) | 2005-01-10 | 2009-05-14 | Glaxo Group Limited | Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions |
WO2006089076A2 (en) | 2005-02-18 | 2006-08-24 | Neurogen Corporation | Thiazole amides, imidazole amides and related analogues |
US20060264433A1 (en) | 2005-05-23 | 2006-11-23 | Backes Bradley J | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
WO2007011759A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
TW200800946A (en) | 2005-08-15 | 2008-01-01 | Astrazeneca Ab | Substituted piperazines as metabotropic glutamate receptor antagonists |
CA2619881A1 (en) | 2005-08-16 | 2007-02-22 | Genzyme Corporation | Chemokine receptor binding compounds |
CA2644368A1 (en) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
CN101460161A (zh) | 2006-03-29 | 2009-06-17 | 弗尔德里克斯制药股份有限公司 | α-突触核蛋白毒性的抑制 |
US7585868B2 (en) | 2006-04-04 | 2009-09-08 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists |
GB0608820D0 (en) | 2006-05-04 | 2006-06-14 | Piramed Ltd | Pharmaceutical compounds |
WO2008016123A1 (fr) | 2006-08-03 | 2008-02-07 | Takeda Pharmaceutical Company Limited | INHIBITEUR DE LA GSK-3β |
WO2008020229A2 (en) | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Antibacterial pyrrolecarboxamides |
EP2054390B1 (en) | 2006-08-25 | 2012-04-11 | Abbott Laboratories | Indazole derivatives that inhibit trpv1 and uses thereof |
US20100022541A1 (en) | 2006-09-25 | 2010-01-28 | Sonia Escaich | Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors |
BRPI0717564A2 (pt) | 2006-09-29 | 2013-10-22 | Novartis Ag | Pirazolopirimidinas como inibidores de pi3k lipídeo cinase |
TWI404532B (zh) | 2006-11-02 | 2013-08-11 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
GB0701426D0 (en) | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
US8450348B2 (en) | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
JP2010116389A (ja) | 2008-10-17 | 2010-05-27 | Bayer Cropscience Ag | 殺虫性アリールピロリジン類 |
US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
EP2170884A2 (en) | 2007-06-25 | 2010-04-07 | Boehringer Ingelheim International GmbH | Chemical compounds |
ES2395081T3 (es) | 2007-07-26 | 2013-02-08 | Vitae Pharmaceuticals, Inc. | Síntesis de inhibidores de la 11beta-hidroxiesteroide deshidrogenasa de tipo 1 |
US8242111B2 (en) | 2008-05-01 | 2012-08-14 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
US8569292B2 (en) | 2008-05-01 | 2013-10-29 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
JP5538365B2 (ja) | 2008-05-01 | 2014-07-02 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状阻害剤 |
ES2421537T3 (es) | 2008-05-01 | 2013-09-03 | Vitae Pharmaceuticals Inc | Inhibidores cíclicos de la 11beta-hidroxiesteroide deshidrogenasa 1 |
WO2009147188A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Benzpyrazol derivatives as inhibitors of pi3 kinases |
ATE552255T1 (de) | 2008-06-05 | 2012-04-15 | Glaxo Group Ltd | 4-aminoindazole |
JP5502858B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | Pi3キナーゼの阻害剤として有用な4−カルボキサミドインダゾール誘導体 |
ES2526966T3 (es) | 2008-06-05 | 2015-01-19 | Glaxo Group Limited | Compuestos novedosos |
US10322469B2 (en) | 2008-06-11 | 2019-06-18 | Hamamatsu Photonics K.K. | Fusion bonding process for glass |
PL2324018T3 (pl) | 2008-07-25 | 2014-02-28 | Boehringer Ingelheim Int | Cykliczne inhibitory dehydrogenazy 11 beta-hydroksysteroidowej typu 1 |
WO2010068287A2 (en) | 2008-12-11 | 2010-06-17 | Angion Biomedica Corp. | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
EP2963116B1 (en) | 2009-03-04 | 2020-11-11 | CuRNA, Inc. | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1 |
JP5656880B2 (ja) * | 2009-03-09 | 2015-01-21 | グラクソ グループ リミテッドGlaxo Group Limited | Pi3キナーゼの阻害剤としての4−オキサジアゾール−2−イル−インダゾール |
US8343959B2 (en) | 2009-04-30 | 2013-01-01 | Abbott Gmbh & Co. Kg | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
PE20120881A1 (es) | 2009-04-30 | 2012-08-24 | AbbVie Deutschland GmbH and Co KG | Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) como moduladores del receptor de serotonina 5-ht6 |
WO2010124845A1 (en) | 2009-04-30 | 2010-11-04 | Bayer Cropscience Ag | Pesticidal arylpyrrolidines |
UA109255C2 (ru) | 2009-04-30 | 2015-08-10 | Берінгер Інгельхайм Інтернешнл Гмбх | Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1 |
GEP20156309B (en) | 2009-04-30 | 2015-07-10 | Vitae Pharmaceuticals Inc | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
AU2010243613B2 (en) * | 2009-04-30 | 2015-05-07 | Glaxo Group Limited | Oxazole substituted indazoles as PI3-kinase inhibitors |
US20120245171A1 (en) | 2009-12-03 | 2012-09-27 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of pi3 kinases |
WO2011067366A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
US20120238559A1 (en) | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Novel compounds |
HUE026059T2 (en) | 2010-09-08 | 2016-05-30 | Glaxosmithkline Ip Dev Ltd | N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazol-6-yl ] Polymorphs and salts of 2 - (methyloxy) -3-pyridinyl] methanesulfonamide |
US9326987B2 (en) * | 2010-09-08 | 2016-05-03 | Glaxo Group Limited | Indazole derivatives for use in the treatment of influenza virus infection |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
-
2010
- 2010-10-27 GB GBGB1018124.6A patent/GB201018124D0/en not_active Ceased
-
2011
- 2011-10-25 LT LTEP11776738.4T patent/LT2632921T/lt unknown
- 2011-10-25 EP EP11776738.4A patent/EP2632921B1/en active Active
- 2011-10-25 US US13/879,667 patent/US8993576B2/en active Active
- 2011-10-25 EA EA201390457A patent/EA022872B1/ru not_active IP Right Cessation
- 2011-10-25 SI SI201131625T patent/SI2632921T1/sl unknown
- 2011-10-25 JP JP2013535398A patent/JP5894603B2/ja active Active
- 2011-10-25 HU HUE11776738A patent/HUE042754T2/hu unknown
- 2011-10-25 RS RS20181547A patent/RS58072B1/sr unknown
- 2011-10-25 MX MX2013004783A patent/MX347619B/es active IP Right Grant
- 2011-10-25 PT PT11776738T patent/PT2632921T/pt unknown
- 2011-10-25 AU AU2011322649A patent/AU2011322649B2/en not_active Ceased
- 2011-10-25 TR TR2018/19939T patent/TR201819939T4/tr unknown
- 2011-10-25 ES ES11776738T patent/ES2703716T3/es active Active
- 2011-10-25 BR BR112013010126-1A patent/BR112013010126B1/pt active IP Right Grant
- 2011-10-25 CN CN201180062847.7A patent/CN103270037B/zh active Active
- 2011-10-25 CA CA2814436A patent/CA2814436C/en active Active
- 2011-10-25 KR KR1020137013540A patent/KR101774026B1/ko active IP Right Grant
- 2011-10-25 SG SG2013023825A patent/SG189179A1/en unknown
- 2011-10-25 WO PCT/EP2011/068604 patent/WO2012055846A1/en active Application Filing
- 2011-10-25 PL PL11776738T patent/PL2632921T3/pl unknown
- 2011-10-25 DK DK11776738.4T patent/DK2632921T3/en active
- 2011-10-25 EP EP18199476.5A patent/EP3447055A1/en not_active Withdrawn
-
2013
- 2013-04-05 ZA ZA2013/02480A patent/ZA201302480B/en unknown
- 2013-04-11 IL IL225704A patent/IL225704A/en active IP Right Grant
-
2018
- 2018-12-06 HR HRP20182059TT patent/HRP20182059T1/hr unknown
- 2018-12-28 CY CY20181101406T patent/CY1121248T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013010126A8 (pt) | polimorfo, composto, composição farmacêutica, uso do polimorfo ou sal, e, método de tratar um distúrbio mediado pela atividade inapropriada de pi3-cinase | |
BR112015003376A8 (pt) | composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica | |
BR112014014769A2 (pt) | Composto, composição farmacêutica, e, uso de um composto ou sal. | |
BR112014003681A2 (pt) | composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições | |
BR112014011671A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto | |
BR112014010179A8 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
BR112015004547A8 (pt) | compostos, composição farmacêutica, uso de um composto e método para o tratamento ou melhoria do cãncer | |
BR112012022878A2 (pt) | composto, composição farmacêutica, uso do compostos e método de tratamento | |
BR112013025353A8 (pt) | combinação de a) um composto de fórmula ia, composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, método para tratamento de um distúrbio hiperproliferativo em um mamífero, uso de um composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, kit e produto | |
BR112014029115A2 (pt) | composto, composição farmacêutica, e, uso de um composto ou composição | |
BR112014031263A2 (pt) | composto, composição farmacêutica, métodos para inibir a secreção wnt e para inibir sinalização wnt, uso do composto ou sal e método para tratar um distúrbio. | |
BR112012003578A2 (pt) | composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal. | |
BR112014010197A2 (pt) | composto, composição farmacêutica, método de tratamento de um distúrbio | |
BR112014006420A2 (pt) | compostos, composição farmacêutica, uso de um composto e mètodo para o tratamento ou profilaxia | |
BR112013026410A2 (pt) | compostos antimicrobianos e métodos de preparação e uso dos mesmos | |
BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
BR112014032510A2 (pt) | composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto. | |
BR112014005669A2 (pt) | composto, composição farmacêutica e uso de um composto | |
BR112012026570A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado | |
BR112014007203A2 (pt) | composto, composição farmacêutica, método de tratamento, utilização de um composto, conjunto e invenção | |
BR112014008241A2 (pt) | composto, composição farmacêutica, métodos para tratar, controlar, retardar ou prevenir doenças e distúrbios, e para preparar um composto, e, uso de um composto | |
BR112013013522A2 (pt) | polinucleotídeo ou um sal deste, composição farmacêutica, uso de um polinucleotídeo ou um sal deste, reagente, composição, e, método para produzir um composto | |
BRPI1013988A2 (pt) | composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo | |
BR112014013177A2 (pt) | composto, composição farmacêutica e uso de um composto | |
BRPI1007624A2 (pt) | composto, método para preparar uma composição, composto ou sal farmaceuticamente aceitável deste e uso de um composto ou um sal farmaceuticamente aceitável deste |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/10/2011, OBSERVADAS AS CONDICOES LEGAIS. |